Merck gets positive EU CHMP opinion for Keytruda plus Chemotherapy as first-line treatment for adult patients with unresectable non-eithelioid Malignant Pleural Mesothelioma Ruchika Sharma19 Nov 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Submit preclinical data in animal and Phase I CT data: CDSCO Panel Tells IQVIA on Pembrolizumab study Dr. Divya Colin2 Nov 2024 6:00 PM ISTNew Delhi: After reviewing the Phase I/III clinical study protocol of the anti-cancer drug Pembrolizumab, the Subject Expert Committee (SEC)...
MSD Phase 3 trial of head and neck cancer treatment meets primary endpoint Ruchika Sharma13 Oct 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA...
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers Ruchika Sharma24 Sept 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Merck discontinues Phase 3 trial for lung cancer combo drug Ruchika Sharma11 Aug 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the Phase 3 KeyVibe-008 trial based on...
Roche to halt lung cancer treatment trial Ruchika Sharma8 July 2024 5:43 PM ISTBased on these results, patients and investigators will be unblinded and we intend to halt the study.
Merck discontinues Vibostolimab, Pembrolizumab coformulation arm of Phase 3 KeyVibe-010 trial in Melanoma Ruchika Sharma14 May 2024 4:17 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the vibostolimab and pembrolizumab...
Merck gets Canadian nod for Keytruda in combo with fluoropyrimidine- and platinum-containing-chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma Ruchika Sharma23 April 2024 3:08 PM ISTKirkland: Merck, known as MSD outside the United States and Canada, has announced that Health Canada has granted approval of KEYTRUDA...
EMA validates Type II variation application for Padcev with Keytruda for first line treatment of advanced Bladder Cancer: Pfizer Ruchika Sharma28 Jan 2024 10:00 AM ISTTokyo: Astellas Pharma Inc. and Pfizer Inc. have announced that the European Medicines Agency (EMA) has validated for review a Type II...
Merck announces positive results from phase 2 trial evaluating coformulation of vibostolimab, pembrolizumab in lung cancer patients Ruchika Sharma10 Dec 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced full results from the non-registrational Phase 2 KeyVibe-002...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
MSD wins DCGI nod for Keytruda for treatment of triple negative breast cancer, renal cell carcinoma Ruchika Sharma26 Oct 2023 11:32 AM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
